DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR CLARITIN-D 24 HOUR

« Back to Dashboard

Clinical Trials for Claritin-d 24 Hour

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00550550	Efficacy and Safety of Grass Sublingual Tablet in Children and Adolescents (P05239 AM3)(COMPLETED)	Completed	Merck Sharp & Dohme Corp.	Phase 3	2007-11-01	The purpose of the study is to investigate the efficacy and safety of a grass sublingual tablet in children and adolescents with a history of grass-pollen induced rhinoconjunctivitis with or without asthma.
NCT00562159	Efficacy and Safety of Grass Sublingual Tablet in Adults (P05238 AM3)(COMPLETED)	Completed	Merck Sharp & Dohme Corp.	Phase 3	2007-11-01	This purpose of this study is to determine the efficacy and safety of a grass sublingual (under-the-tongue) tablet.
NCT00762983	Observation of Use of Claritin (Loratadine) Tablet, RediTabs, and Dry Syrup in Children (Study P05834)(COMPLETED)	Completed	Merck Sharp & Dohme Corp.	N/A	2008-03-01	The purpose of this study is to collect information on unexpected adverse reactions (ADRs), how often ADRs occur, and factors that can affect the safety and effectiveness of Claritin (loratadine) when used in children. Patients will be observed while they are taking Claritin, and ADRs and symptom scores will be recorded. At the end of treatment, improvement in symptoms will be recorded. Post-marketing surveys are not considered applicable clinical trials and thus the results of this survey will not be posted at its conclusion. The results will be submitted to public health officials as required by applicable national and international laws.
NCT00776217	Bioequivalence Study on Loratadine Orally Disintegrating Tablets 10 mg Under Fasting Conditions	Completed	Ranbaxy Laboratories Limited	N/A	2006-06-01	To compare the single-dose oral bioavailability of loratadine 10 mg orally disintegrating tablets of Ohm Laboratories (a subsidiary of Ranbaxy Pharmaceuticals Inc., USA) with Claritin® Reditabs® (containing loratadine 10 mg) of Schering-Plough Healthcare Product Inc., USA in healthy, adult, human male subjects under fasting condition.

Clinical Trial Conditions for Claritin-d 24 Hour

Condition Name

Condition Name for Claritin-d 24 Hour
Intervention	Trials
Healthy	5
Allergy	3
Flu Symptoms	2
Rhinitis	2

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Claritin-d 24 Hour
Intervention	Trials
Rhinitis	6
Rhinitis, Allergic	4
Conjunctivitis	2
Rhinitis, Allergic, Seasonal	2

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Claritin-d 24 Hour

Trials by Country

Trials by Country for Claritin-d 24 Hour
Location	Trials
United States	8
Canada	3
Brazil	3
Germany	1

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Claritin-d 24 Hour
Location	Trials
Kentucky	3
New Jersey	2
Michigan	1
Maryland	1
Illinois	1

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Claritin-d 24 Hour

Clinical Trial Phase

Clinical Trial Phase for Claritin-d 24 Hour
Clinical Trial Phase	Trials
Phase 4	6
Phase 3	5
Phase 2	1

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Claritin-d 24 Hour
Clinical Trial Phase	Trials
Completed	15
Not yet recruiting	3
Unknown status	2

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Claritin-d 24 Hour

Sponsor Name

Sponsor Name for Claritin-d 24 Hour
Sponsor	Trials
Ranbaxy Laboratories Limited	4
Bayer	4
Merck Sharp & Dohme Corp.	3

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Claritin-d 24 Hour
Sponsor	Trials
Industry	20
Other	5
NIH	1

Export unavailable in trial.
Subscribe for complete access.